Please use this identifier to cite or link to this item:
Type: Artigo
Title: 2-aryl-3-(2-morpholinoethyl)thiazolidin-4-ones: Synthesis, Anti-inflammatory In Vivo, Cytotoxicity In Vitro And Molecular Docking Studies
Author: Gouvea
Daniela Pires; Vasconcellos
Flavia Aleixo; Berwaldt
Gabriele dos Anjos; Pinto Seixas Neto
Amilton Clair; Fischer
Gerferson; Sakata
Renata Parruca; Almeida
Wanda Pereira; Cunico
Abstract: Seven new 4-thiazolidinones bearing the morpholino moiety were easily synthesized by one-pot reactions of 4-(2-aminoethyl)morpholine (2-morpholinoethylamine), arenealdehydes and mercaptoacetic acid refluxing toluene for 19 h with moderate to good yields (45-97%). These novel compounds were fully identified and characterized by NMR spectroscopy and mass spectrometry. Thiazolidin-4-ones in vivo anti-inflammatory activities were determined using a croton oil-induced ear edema model of inflammation in BALB C mice. The best results were found for compounds 4c (49.20 mmol/kg), 4d (49.20 mmol/kg) and 4f (52.48 mmol/kg), which showed the ability to decrease the ear edema in mice by 50%, 48% and 54%, respectively, when compared to the standard drug indomethacin. In addition, the in vitro cytotoxicity activity of thiazolidin-4-ones against Vero cells was also performed and four compounds (4a, 4c, 4d and 4f) showed no toxic effect at 500 mu g/mL. A docking simulation of compounds into the 1Q4G (COX-1) and 4PH9 (COX-2) enzymes binding site was conducted. This preliminary result will guide us in for further studies to improve the anti-inflammatory activity. (C) 2016 Elsevier Masson SAS. All rights reserved.
Subject: Thiazolidin-4-ones
Anti-inflammatory Activity
Ear Edema
Molecular Docking
Editor: Elsevier France-Editions Scientifiques Medicales Elsevier
Rights: fechado
Identifier DOI: 10.1016/j.ejmech.2016.04.028
Date Issue: 2016
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000377312400023.pdf732.32 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.